BIONi010-C CD33 KO
BIONi010-C-9
General#
Cell Line |
|
| hPSCreg Name | BIONi010-C-9 |
| Alternative name(s) |
BIONi010-C CD33 KO
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 16th February 2021 |
| Notes | KO for CD33. No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23 |
| User feedback | |
Provider |
|
| Generator |
Bioneer (BION)
Contact:
Bioneer (BION) |
| Owner | Bioneer (BION) |
| Distributors | |
| Derivation country | Denmark |
External Databases |
|
| BioSamples | SAMEA4454012 |
| Cellosaurus | CVCL_LL40 |
| ECACC | 66540371 |
| EBiSC | BIONi010-C-9 |
| CLO | CLO_0102723 |
General Information |
|
| Publications |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research: allowed
Clinical: allowed
Commercial: allowed
|
| Subclone of | |
Donor Information#
General Donor Information |
|
| Sex | male |
| Ethnicity | Black or African-American |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA3105780 |
Ethics#
Also have a look at the ethics information for the parental line
BIONi010-C
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation#
General |
|
|
The source cell information can be found in the parental cell line
BIONi010-C.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 18 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
30
|
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755 This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768 |
Genetic Modification#
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.